These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28610791)

  • 21. Potential of Casiopeínas® Copper Complexes and Antituberculosis Drug Combination against Mycobacterium tuberculosis.
    Barbosa AR; Caleffi-Ferracioli KR; Leite CQ; García-Ramos JC; Toledano-Magaña Y; Ruiz-Azuara L; Siqueira VL; Pavan FR; Cardoso RF
    Chemotherapy; 2016; 61(5):249-55. PubMed ID: 26950478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.
    Andries K; Verhasselt P; Guillemont J; Göhlmann HW; Neefs JM; Winkler H; Van Gestel J; Timmerman P; Zhu M; Lee E; Williams P; de Chaffoy D; Huitric E; Hoffner S; Cambau E; Truffot-Pernot C; Lounis N; Jarlier V
    Science; 2005 Jan; 307(5707):223-7. PubMed ID: 15591164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal whole genome analysis of pre and post drug treatment Mycobacterium tuberculosis isolates reveals progressive steps to drug resistance.
    Datta G; Nieto LM; Davidson RM; Mehaffy C; Pederson C; Dobos KM; Strong M
    Tuberculosis (Edinb); 2016 May; 98():50-5. PubMed ID: 27156618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro evaluation of dinactin, a potent microbial metabolite against Mycobacterium tuberculosis.
    Hussain A; Rather MA; Bhat ZS; Majeed A; Maqbool M; Shah AM; Aga MA; Shah A; Mushtaq S; Sangwan PL; Hassan QP; Ahmad Z
    Int J Antimicrob Agents; 2019 Jan; 53(1):49-53. PubMed ID: 30267759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro.
    Chen P; Gearhart J; Protopopova M; Einck L; Nacy CA
    J Antimicrob Chemother; 2006 Aug; 58(2):332-7. PubMed ID: 16751637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro interaction of eupomatenoid-5 from Piper solmsianum C. DC. var. solmsianum and anti-tuberculosis drugs.
    Lopes MA; Ferracioli KR; Siqueira VL; de Lima Scodro RB; Cortez DA; da Silva RZ; Cardoso RF
    Int J Tuberc Lung Dis; 2014 Dec; 18(12):1513-5. PubMed ID: 25517821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination.
    Pagliotto AD; Caleffi-Ferracioli KR; Lopes MA; Baldin VP; Leite CQ; Pavan FR; Scodro RB; Siqueira VL; Cardoso RF
    J Microbiol Immunol Infect; 2016 Dec; 49(6):980-983. PubMed ID: 26454420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing.
    Valvatne H; Syre H; Kross M; Stavrum R; Ti T; Phyu S; Grewal HM
    J Antimicrob Chemother; 2009 Oct; 64(4):694-701. PubMed ID: 19710078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of anti-tuberculosis drugs with vitamin C or NAC against different Staphylococcus aureus and Mycobacterium tuberculosis strains.
    Khameneh B; Fazly Bazzaz BS; Amani A; Rostami J; Vahdati-Mashhadian N
    Microb Pathog; 2016 Apr; 93():83-7. PubMed ID: 26602814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
    Jindani A; Doré CJ; Mitchison DA
    Am J Respir Crit Care Med; 2003 May; 167(10):1348-54. PubMed ID: 12519740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
    Bhusal Y; Shiohira CM; Yamane N
    Int J Antimicrob Agents; 2005 Oct; 26(4):292-7. PubMed ID: 16150578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of Moxifloxacin against
    Louie A; Duncanson B; Myrick J; Maynard M; Nole J; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Drusano GL
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress on mechanism of ethambutol resistance in Mycobacterium Tuberculosis.
    Wang T; Jiao WW; Shen AD
    Yi Chuan; 2016 Oct; 38(10):910-917. PubMed ID: 27806932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis.
    Dickinson JM; Aber VR; Mitchison DA
    Am Rev Respir Dis; 1977 Oct; 116(4):627-35. PubMed ID: 411404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis model.
    de Knegt GJ; Dickinson L; Pertinez H; Evangelopoulos D; McHugh TD; Bakker-Woudenberg IAJM; Davies GR; de Steenwinkel JEM
    Tuberculosis (Edinb); 2017 Jul; 105():113-118. PubMed ID: 28610782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enabling faster Go/No-Go decisions through secondary screens in anti-mycobacterial drug discovery.
    Mukherjee R; Chandra Pal A; Banerjee M
    Tuberculosis (Edinb); 2017 Sep; 106():44-52. PubMed ID: 28802404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug resistance to the first line of antitubercular regimen (a preliminary report).
    Varaiya A; Gogate A
    Indian J Public Health; 1998; 42(4):126-30. PubMed ID: 10389525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol.
    Srivastava S; Musuka S; Sherman C; Meek C; Leff R; Gumbo T
    J Infect Dis; 2010 Apr; 201(8):1225-31. PubMed ID: 20210628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.